Aims The objective of this study was to assess the effect of HER2-directed therapy (HER2-
Tx) on peripheral vasoreactivity and its correlation with cardiac function changes and the …

Background: Anthracycline cardiotoxicity (AC) may manifest years after treatment (long-term
cardiotoxicity). There is little data on the incidence and natural history of AC in the current …

The sequential or concurrent use of two different types of agents such as anthracyclines and
trastuzumab may increase myocardial injury and cancer therapeutics-related cardiac …

Aims The aim is to study the action and effects of antitumor polychemotherapy (PCT) with
Anthracyclines on the cardiovascular system performance in primary oncological patients …

The prevalence of breast cancer in women is a fundamental problem in public health
worldwide. There is consensual evidence that many chemotherapeutic agents might have …

Anthracycline-containing chemotherapy (A-CHT) can induce late cardiotoxicity adding a
considerable burden to cardiovascular risk. Irradiation of left breast cancer has also been …

Cardiovascular (CV) diseases (CVD) are a major cause of long-term morbidity and mortality
affecting life expectancy amongst cancer survivors. In recent years, because of the …

Introduction Cardiotoxicity represents a major limitation for the use of anthracyclines or
trastuzumab in breast cancer patients. Data on longitudinal studies about early and late …

Advances in oncologic therapies have allowed to achieve better outcomes and longer
survival in many patients with breast cancer. Anthracyclines are cytotoxic antibiotics widely …

Background Anthracyclines are associated with cardiotoxic effects. Cardiovascular
biomarkers may reflect myocardial injury, dysfunction, inflammation, and fibrosis and may …